Determinants of antileukemia effects of allogeneic NK cells - PubMed (original) (raw)
Clinical Trial
. 2004 Jan 1;172(1):644-50.
doi: 10.4049/jimmunol.172.1.644.
Affiliations
- PMID: 14688377
- DOI: 10.4049/jimmunol.172.1.644
Clinical Trial
Determinants of antileukemia effects of allogeneic NK cells
Wing Leung et al. J Immunol. 2004.
Abstract
In HLA-nonidentical bone marrow transplantation, we studied the characteristics of donor NK cells, recipient leukemia cells, and the cytokine environment that predict the antileukemia effects of allogeneic NK cells. We found that the risk of relapse in pediatric patients with hematologic malignancies was best predicted by a model taking into consideration the presence of inhibitory killer cell Ig-like receptors (KIRs) on the donor's NK cells and the absence of corresponding KIR ligand in the recipient's HLA repertoire (a receptor-ligand model). The risk of relapse was prognosticated less precisely by the Perugia donor-recipient KIR ligand-ligand mismatch model or by a natural cytotoxicity model. In contrast to the ligand-ligand model, we found that the new receptor-ligand model was accurate when analysis was applied to patients with lymphoid malignancy. These findings corroborate our observations that the recipient's KIR repertoire, which was derived from highly purified, HLA-disparate CD34+ cells, resumed a donor-specific pattern within 3 mo of transplantation, but did not correlate evidently with the donor or recipient ligand repertoire. In an in vitro assay and an in vivo mouse model, human NK cell cytotoxicity toward human leukemia cells with 11q23 chromosomal rearrangement increased with the number of receptor-ligand mismatch pairs or prestimulation with IL-12 and IL-18. These findings provide new insights into the determinants of antileukemia effects of allogeneic NK cells and therapeutic strategies.
Similar articles
- [Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].
Bao XJ, He J, Chen ZX, Wu DP, Yao L, Yuan XN, Cen JN, Qiu QC, Di WY, Zhang H, Zhang J, Zhou XH, Xu HX. Bao XJ, et al. Zhonghua Xue Ye Xue Za Zhi. 2007 Aug;28(8):510-3. Zhonghua Xue Ye Xue Za Zhi. 2007. PMID: 18078124 Chinese. - [KIRs on human NK cells and in relation with HLA class I antigen--review].
Dou LP, Da WM. Dou LP, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):627-30. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006. PMID: 16800958 Review. Chinese. - Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW. Igarashi T, et al. Blood. 2004 Jul 1;104(1):170-7. doi: 10.1182/blood-2003-12-4438. Epub 2004 Mar 11. Blood. 2004. PMID: 15016654 - Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY, Yu XX, Xu ZL, Cao XH, Huo MR, Zhao XS, Chang YJ, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ. Zhao XY, et al. Blood Adv. 2019 Dec 23;3(24):4312-4325. doi: 10.1182/bloodadvances.2019000242. Blood Adv. 2019. PMID: 31869417 Free PMC article. - Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, Martelli MF, Velardi A. Ruggeri L, et al. Semin Cancer Biol. 2006 Oct;16(5):404-11. doi: 10.1016/j.semcancer.2006.07.007. Epub 2006 Jul 8. Semin Cancer Biol. 2006. PMID: 16916611 Review.
Cited by
- Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.
Naik S, Li Y, Talleur AC, Selukar S, Ashcraft E, Cheng C, Madden RM, Mamcarz E, Qudeimat A, Sharma A, Srinivasan A, Suliman AY, Epperly R, Obeng EA, Velasquez MP, Langfitt D, Schell S, Métais JY, Arnold PY, Hijano DR, Maron G, Merchant TE, Akel S, Leung W, Gottschalk S, Triplett BM. Naik S, et al. J Hematol Oncol. 2024 Jun 27;17(1):50. doi: 10.1186/s13045-024-01567-0. J Hematol Oncol. 2024. PMID: 38937803 Free PMC article. Clinical Trial. - The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
Hadjis AD, McCurdy SR. Hadjis AD, et al. Front Immunol. 2024 May 16;15:1358668. doi: 10.3389/fimmu.2024.1358668. eCollection 2024. Front Immunol. 2024. PMID: 38817602 Free PMC article. Review. - Donor KIR2DL1 Allelic Polymorphism Influences Posthematopoietic Progenitor Cell Transplantation Outcomes in the T Cell Depleted and Reduced Intensity Conditioning Setting.
Wright PA, van de Pasch LAL, Dignan FL, Kichula KM, Pollock NR, Norman PJ, Marchan E, Hill L, Vandelbosch S, Fullwood C, Sheldon S, Hampson L, Tholouli E, Poulton KV. Wright PA, et al. Transplant Cell Ther. 2024 May;30(5):488.e1-488.e15. doi: 10.1016/j.jtct.2024.02.014. Epub 2024 Feb 17. Transplant Cell Ther. 2024. PMID: 38369017 - Impact of KIR-HLA Genotype on Natural-Killer-Cell-Based Immunotherapy for Preventing Hepatocellular Carcinoma after Living-Donor Liver Transplantation.
Tanimine N, Ohira M, Kurita E, Nakano R, Sakai H, Tahara H, Ide K, Kobayashi T, Tanaka Y, Ohdan H. Tanimine N, et al. Cancers (Basel). 2024 Jan 26;16(3):533. doi: 10.3390/cancers16030533. Cancers (Basel). 2024. PMID: 38339284 Free PMC article. - Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation.
Di Ianni M, Liberatore C, Santoro N, Ranalli P, Guardalupi F, Corradi G, Villanova I, Di Francesco B, Lattanzio S, Passeri C, Lanuti P, Accorsi P. Di Ianni M, et al. Cells. 2024 Jan 11;13(2):134. doi: 10.3390/cells13020134. Cells. 2024. PMID: 38247827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous